Cargando…

Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII

BACKGROUND: The onset and clinical presentation of systemic lupus erythematosus (SLE) are sex-related. Few studies have investigated the distinctions in clinical characteristics and treatment preferences in male and female SLE patients in the initial cohort. This study aimed to improve the understan...

Descripción completa

Detalles Bibliográficos
Autores principales: Gui, Yinli, Bai, Wei, Xu, Jian, Duan, Xinwang, Zhan, Feng, Zhao, Chen, Jiang, Zhenyu, Li, Zhijun, Wu, Lijun, Liu, Shengyun, Yang, Min, Wei, Wei, Wang, Ziqian, Zhao, Jiuliang, Wang, Qian, Leng, Xiaomei, Tian, Xinping, Li, Mengtao, Zhao, Yan, Zeng, Xiaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771188/
https://www.ncbi.nlm.nih.gov/pubmed/36525605
http://dx.doi.org/10.1097/CM9.0000000000002360
_version_ 1784854766552088576
author Gui, Yinli
Bai, Wei
Xu, Jian
Duan, Xinwang
Zhan, Feng
Zhao, Chen
Jiang, Zhenyu
Li, Zhijun
Wu, Lijun
Liu, Shengyun
Yang, Min
Wei, Wei
Wang, Ziqian
Zhao, Jiuliang
Wang, Qian
Leng, Xiaomei
Tian, Xinping
Li, Mengtao
Zhao, Yan
Zeng, Xiaofeng
author_facet Gui, Yinli
Bai, Wei
Xu, Jian
Duan, Xinwang
Zhan, Feng
Zhao, Chen
Jiang, Zhenyu
Li, Zhijun
Wu, Lijun
Liu, Shengyun
Yang, Min
Wei, Wei
Wang, Ziqian
Zhao, Jiuliang
Wang, Qian
Leng, Xiaomei
Tian, Xinping
Li, Mengtao
Zhao, Yan
Zeng, Xiaofeng
author_sort Gui, Yinli
collection PubMed
description BACKGROUND: The onset and clinical presentation of systemic lupus erythematosus (SLE) are sex-related. Few studies have investigated the distinctions in clinical characteristics and treatment preferences in male and female SLE patients in the initial cohort. This study aimed to improve the understanding of Chinese SLE patients by characterizing the different sexes of SLE patients in the inception cohort. METHODS: Based on the initial patient cohort established by the Chinese SLE Treatment and Research Group, a total of 8713 patients (795 men and 7918 women) with newly diagnosed SLE were enrolled between April 2009 and March 2021. Of these, 2900 patients (347 men and 2553 women) were eligible for lupus nephritis (LN). A cross-sectional analysis of the baseline demographic characteristics, clinical manifestations, laboratory parameters, organ damage, initial treatment regimens, and renal pathology classification was performed according to sex. RESULTS: In the SLE group, as compared to female patients, male patients had a later age of onset (male vs. female: 37.0 ± 15.8 years vs. 35.1 ± 13.7 years, P = 0.006) and a higher SLE International Collaborative Clinic/American College of Rheumatology damage index score (male vs. female: 0.47 ± 1.13 vs. 0.34 ± 0.81, P = 0.015), LN (male vs. female: 43.6% vs. 32.2%, P < 0.001), fever (male vs. female: 18.0% vs. 14.6%, P = 0.010), thrombocytopenia (male vs. female: 21.4% vs. 18.5%, P = 0.050), serositis (male vs. female: 14.7% vs. 11.7%, P = 0.013), renal damage (male vs. female: 11.1% vs. 7.4%, P < 0.001), and treatment with cyclophosphamide (CYC) (P < 0.001). The frequency of leukopenia (male vs. female: 20.5% vs. 25.4%, P = 0.002) and arthritis (male vs. female: 22.0% vs. 29.9%, P < 0.001) was less in male patients with SLE. In LN, no differences were observed in disease duration, SLE Disease Activity Index score, renal biopsy pathological typing, or 24-h urine protein quantification among the sexes. In comparisons with female patients with LN, male patients had later onset ages (P = 0.026), high serum creatinine (P < 0.001), higher end-stage renal failure rates (P = 0.002), musculoskeletal damage (P = 0.023), cardiovascular impairment (P = 0.009), and CYC use (P = 0.001); while leukopenia (P = 0.017), arthritis (P = 0.014), and mycophenolate usage (P = 0.013) rates were lower. CONCLUSIONS: Male SLE patients had more severe organ damage and a higher LN incidence compared with female SLE patients; therefore, they may require more aggressive initial treatment compared to female patients.
format Online
Article
Text
id pubmed-9771188
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97711882022-12-22 Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII Gui, Yinli Bai, Wei Xu, Jian Duan, Xinwang Zhan, Feng Zhao, Chen Jiang, Zhenyu Li, Zhijun Wu, Lijun Liu, Shengyun Yang, Min Wei, Wei Wang, Ziqian Zhao, Jiuliang Wang, Qian Leng, Xiaomei Tian, Xinping Li, Mengtao Zhao, Yan Zeng, Xiaofeng Chin Med J (Engl) Original Articles BACKGROUND: The onset and clinical presentation of systemic lupus erythematosus (SLE) are sex-related. Few studies have investigated the distinctions in clinical characteristics and treatment preferences in male and female SLE patients in the initial cohort. This study aimed to improve the understanding of Chinese SLE patients by characterizing the different sexes of SLE patients in the inception cohort. METHODS: Based on the initial patient cohort established by the Chinese SLE Treatment and Research Group, a total of 8713 patients (795 men and 7918 women) with newly diagnosed SLE were enrolled between April 2009 and March 2021. Of these, 2900 patients (347 men and 2553 women) were eligible for lupus nephritis (LN). A cross-sectional analysis of the baseline demographic characteristics, clinical manifestations, laboratory parameters, organ damage, initial treatment regimens, and renal pathology classification was performed according to sex. RESULTS: In the SLE group, as compared to female patients, male patients had a later age of onset (male vs. female: 37.0 ± 15.8 years vs. 35.1 ± 13.7 years, P = 0.006) and a higher SLE International Collaborative Clinic/American College of Rheumatology damage index score (male vs. female: 0.47 ± 1.13 vs. 0.34 ± 0.81, P = 0.015), LN (male vs. female: 43.6% vs. 32.2%, P < 0.001), fever (male vs. female: 18.0% vs. 14.6%, P = 0.010), thrombocytopenia (male vs. female: 21.4% vs. 18.5%, P = 0.050), serositis (male vs. female: 14.7% vs. 11.7%, P = 0.013), renal damage (male vs. female: 11.1% vs. 7.4%, P < 0.001), and treatment with cyclophosphamide (CYC) (P < 0.001). The frequency of leukopenia (male vs. female: 20.5% vs. 25.4%, P = 0.002) and arthritis (male vs. female: 22.0% vs. 29.9%, P < 0.001) was less in male patients with SLE. In LN, no differences were observed in disease duration, SLE Disease Activity Index score, renal biopsy pathological typing, or 24-h urine protein quantification among the sexes. In comparisons with female patients with LN, male patients had later onset ages (P = 0.026), high serum creatinine (P < 0.001), higher end-stage renal failure rates (P = 0.002), musculoskeletal damage (P = 0.023), cardiovascular impairment (P = 0.009), and CYC use (P = 0.001); while leukopenia (P = 0.017), arthritis (P = 0.014), and mycophenolate usage (P = 0.013) rates were lower. CONCLUSIONS: Male SLE patients had more severe organ damage and a higher LN incidence compared with female SLE patients; therefore, they may require more aggressive initial treatment compared to female patients. Lippincott Williams & Wilkins 2022-09-20 2022-10-20 /pmc/articles/PMC9771188/ /pubmed/36525605 http://dx.doi.org/10.1097/CM9.0000000000002360 Text en Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Original Articles
Gui, Yinli
Bai, Wei
Xu, Jian
Duan, Xinwang
Zhan, Feng
Zhao, Chen
Jiang, Zhenyu
Li, Zhijun
Wu, Lijun
Liu, Shengyun
Yang, Min
Wei, Wei
Wang, Ziqian
Zhao, Jiuliang
Wang, Qian
Leng, Xiaomei
Tian, Xinping
Li, Mengtao
Zhao, Yan
Zeng, Xiaofeng
Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII
title Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII
title_full Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII
title_fullStr Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII
title_full_unstemmed Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII
title_short Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII
title_sort sex differences in systemic lupus erythematosus (sle): an inception cohort of the chinese sle treatment and research group (cstar) registry xvii
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771188/
https://www.ncbi.nlm.nih.gov/pubmed/36525605
http://dx.doi.org/10.1097/CM9.0000000000002360
work_keys_str_mv AT guiyinli sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT baiwei sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT xujian sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT duanxinwang sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT zhanfeng sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT zhaochen sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT jiangzhenyu sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT lizhijun sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT wulijun sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT liushengyun sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT yangmin sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT weiwei sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT wangziqian sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT zhaojiuliang sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT wangqian sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT lengxiaomei sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT tianxinping sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT limengtao sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT zhaoyan sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii
AT zengxiaofeng sexdifferencesinsystemiclupuserythematosussleaninceptioncohortofthechinesesletreatmentandresearchgroupcstarregistryxvii